MANTLE CELL LYMPHOMA (MCL)
Clinical trials for MANTLE CELL LYMPHOMA (MCL) explained in plain language.
Never miss a new study
Get alerted when new MANTLE CELL LYMPHOMA (MCL) trials appear
Sign up with your email to follow new studies for MANTLE CELL LYMPHOMA (MCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New CAR t therapy aims to stop High-Risk lymphoma early
Disease control Not yet recruitingThis study tests a new treatment called MB-CART2019.1 (Zamtocabtagene autoleucel) for people with a fast-growing type of blood cancer called high-risk mantle cell lymphoma. The treatment uses a patient's own immune cells, modified to attack cancer cells, given soon after initial …
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated May 26, 2026 05:45 UTC
-
New combo therapy targets hard-to-treat lymphoma after standard drugs fail
Disease control Not yet recruitingThis study tests a combination of four drugs (zuberitamab, selinexor, dexamethasone, and thalidomide) in 30 adults aged 18-70 with mantle cell lymphoma that has returned or not responded after BTK inhibitor treatment. The goal is to improve remission rates and extend survival wit…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE4 • Sponsor: Zhengzhou University • Aim: Disease control
Last updated May 26, 2026 05:44 UTC
-
Colombia launches first CAR-T trial for relapsed blood cancers
Disease control Not yet recruitingThis study aims to bring a personalized cell therapy called CAR-T to Colombia for people with certain blood cancers that have come back or not responded to treatment. The therapy involves modifying a patient's own immune cells to attack cancer. The trial will check if it is safe …
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: NA • Sponsor: GUSTAVO SALGUERO • Aim: Disease control
Last updated May 19, 2026 11:48 UTC